| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Risperidone for chronic schizophrenia. The Medical letter on drugs and therapeutics. vol 36. issue 920. 1994-05-04. PMID:7511777. |
risperidone for chronic schizophrenia. |
1994-05-04 |
2023-08-12 |
Not clear |
| Risperidone and remoxipride for schizophrenia. Drug and therapeutics bulletin. vol 31. issue 26. 1994-03-17. PMID:7508364. |
risperidone and remoxipride for schizophrenia. |
1994-03-17 |
2023-08-12 |
Not clear |
| D E Addington, B Jones, D Bloom, G Chouinard, G Remington, P Albrigh. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical therapeutics. vol 15. issue 5. 1994-02-03. PMID:7505716. |
a new antipsychotic agent, risperidone, has demonstrated efficacy against both positive and negative symptoms of schizophrenia and has been associated with a low incidence of eps. |
1994-02-03 |
2023-08-12 |
Not clear |
| G Chouinard, W Arnot. Clinical review of risperidone. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 38 Suppl 3. 1994-01-13. PMID:7504574. |
phase ii clinical trials with risperidone have proven it to have a potent antipsychotic effect, improving both positive and negative symptoms of schizophrenia. |
1994-01-13 |
2023-08-12 |
Not clear |
| G Chouinard, W Arnot. Clinical review of risperidone. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 38 Suppl 3. 1994-01-13. PMID:7504574. |
one-year data on risperidone suggest that its therapeutic action in patients with chronic schizophrenia can be maintained without the significant neurological side-effects associated with the use of standard neuroleptics. |
1994-01-13 |
2023-08-12 |
Not clear |
| G Chouinard, B Jones, G Remington, D Bloom, D Addington, G W MacEwan, A Labelle, L Beauclair, W Arnot. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of clinical psychopharmacology. vol 13. issue 1. 1993-06-10. PMID:7683702. |
in a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central 5-hydroxytryptamine2 and dopamine d2 antagonist), 2, 6, 10, 16 mg/day; haloperidol, 20 mg/day; or placebo, after a single-blind placebo washout period. |
1993-06-10 |
2023-08-12 |
Not clear |
| R L Borison, A P Pathiraja, B I Diamond, R C Meibac. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology bulletin. vol 28. issue 2. 1992-10-01. PMID:1381102. |
risperidone: clinical safety and efficacy in schizophrenia. |
1992-10-01 |
2023-08-11 |
Not clear |
| S R Marde. Risperidone: clinical development: north American results. Clinical neuropharmacology. vol 15 Suppl 1 Pt A. 1992-09-14. PMID:1379883. |
this multicenter trial indicates that risperidone is an effective treatment for the positive and negative symptoms of schizophrenia. |
1992-09-14 |
2023-08-11 |
Not clear |
| J E Leysen, P M Janssen, W Gommeren, J Wynants, P J Pauwels, P A Jansse. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Molecular pharmacology. vol 41. issue 3. 1992-04-16. PMID:1372084. |
risperidone and ocaperidone are new benzisoxazol antipsychotics with particularly beneficial effects in schizophrenia. |
1992-04-16 |
2023-08-11 |
human |
| J F Castelão, L Ferreira, Y G Gelders, S L Heyle. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study. Schizophrenia research. vol 2. issue 4-5. 1991-03-08. PMID:2484825. |
after a wash-out period of 1 week, 20 patients suffering from schizophrenia were treated for 4 weeks in an open dose-finding study with a new serotonin-dopamine antagonist risperidone. |
1991-03-08 |
2023-08-11 |
Not clear |
| C J Niemegeers, F Awouters, P A Jansse. [Serotonin antagonism involved in the antipsychotic effect. Confirmation with ritanserine and risperidone]. L'Encephale. vol 16. issue 2. 1990-07-18. PMID:1693560. |
at doses of 5 mg daily risperidone acts on both negative and positive symptoms of schizophrenia in the virtual absence of eps. |
1990-07-18 |
2023-08-11 |
Not clear |
| T F Meert, P de Haes, P A Jansse. Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats. Psychopharmacology. vol 97. issue 2. 1989-07-03. PMID:2471220. |
the potential clinical effect of risperidone in the positive and negative symptoms of schizophrenia is discussed. |
1989-07-03 |
2023-08-11 |
rat |
| P A Janssen, C J Niemegeers, F Awouters, K H Schellekens, A A Megens, T F Meer. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. The Journal of pharmacology and experimental therapeutics. vol 244. issue 2. 1988-04-12. PMID:2450200. |
the first clinical studies indicate that two additional therapeutic targets, which are not reached with classical neuroleptics, may be obtained with risperidone in the monotherapy of schizophrenia and related disorders: very important contact and mood-elevating properties and extrapyramidal symptoms-free maintenance therapy. |
1988-04-12 |
2023-08-11 |
rat |